BioCentury | Jan 5, 2009
Company News

Repros board of directors update

...Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Business: Genitourinary, Endocrine Appointed: Mark Lappe, managing partner of Efficacy Capital...
BioCentury | Oct 6, 2008
Company News

Repros board of directors update

...Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Business: Genitourinary, Endocrine Appointed: Mark Lappe, managing partner at Efficacy Capital...
BioCentury | Sep 30, 2008
Financial News

Repros raises $15.6 million

...shares at $6.50, which is a 7% premium to Repros' close of $6.08 on Friday. Efficacy Capital...
BioCentury | Mar 3, 2006
Financial News

Arius raises C$24.6 million

...share plus one five-year warrant exercisable at C$1. Investors included OrbiMed Advisors; Xmark Opportunity; and Efficacy Capital...
BioCentury | Feb 1, 2006
Financial News

Arius to raise C$22.8 million

...agents were Dundee; Loewen, Ondaatje, McCutcheon; and Canaccord. Lead investors OrbiMed Advisors; Xmark Opportunity; and Efficacy Capital...
BioCentury | Aug 17, 2005
Financial News

Sonus raises $17.8 million

...deal was announced. Punk, Ziegel was the placement agent. Investors included Domain Public Equity Partners; Efficacy Capital...
Items per page:
1 - 6 of 6
BioCentury | Jan 5, 2009
Company News

Repros board of directors update

...Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Business: Genitourinary, Endocrine Appointed: Mark Lappe, managing partner of Efficacy Capital...
BioCentury | Oct 6, 2008
Company News

Repros board of directors update

...Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Business: Genitourinary, Endocrine Appointed: Mark Lappe, managing partner at Efficacy Capital...
BioCentury | Sep 30, 2008
Financial News

Repros raises $15.6 million

...shares at $6.50, which is a 7% premium to Repros' close of $6.08 on Friday. Efficacy Capital...
BioCentury | Mar 3, 2006
Financial News

Arius raises C$24.6 million

...share plus one five-year warrant exercisable at C$1. Investors included OrbiMed Advisors; Xmark Opportunity; and Efficacy Capital...
BioCentury | Feb 1, 2006
Financial News

Arius to raise C$22.8 million

...agents were Dundee; Loewen, Ondaatje, McCutcheon; and Canaccord. Lead investors OrbiMed Advisors; Xmark Opportunity; and Efficacy Capital...
BioCentury | Aug 17, 2005
Financial News

Sonus raises $17.8 million

...deal was announced. Punk, Ziegel was the placement agent. Investors included Domain Public Equity Partners; Efficacy Capital...
Items per page:
1 - 6 of 6